GBT new logo.png
GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
June 15, 2021 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) has awarded approximately $450,000 to U.S. community-based organizations and...
GBT new logo.png
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
June 14, 2021 07:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and...
GBT new logo.png
Nouvelles données en faveur de l'utilisation d'Oxbryta® (voxelotor) chez des enfants de 4 à 11 ans atteints de drépanocytose, présentées au Congrès Virtuel 2021 de l'Association Européenne d'Hématologie
June 11, 2021 03:05 ET | Global Blood Therapeutics, Inc.
L'analyse de l'étude de Phase 2a HOPE-KIDS 1 fait l'objet d'une présentation orale Deux études en vie réelle ont démontré des améliorations durables du taux d'hémoglobine avec Oxbryta, corroborant...
GBT new logo.png
Neue Belege für die potenzielle Anwendung von Oxbryta® (voxelotor) bei Kindern mit Sichelzellkrankheit im Alter von 4 bis 11 Jahren auf dem virtuellen Kongress der European Hematology Association 2021 vorgestellt
June 11, 2021 03:05 ET | Global Blood Therapeutics, Inc.
Analyse der Phase-2a-Studie HOPE-KIDS 1 in oraler Präsentation vorgestellt Zwei Studien mit real world Daten zeigten nachhaltige Verbesserungen des Hämoglobins mit Oxbryta, im Einklang mit den...
GBT new logo.png
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
June 11, 2021 03:05 ET | Global Blood Therapeutics, Inc.
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the...
GBT new logo.png
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
June 11, 2021 03:00 ET | Global Blood Therapeutics, Inc.
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the...
GBT new logo.png
GBT Announces New Employment Inducement Grants
June 04, 2021 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2021, the compensation committee of GBT’s board of...
GBT new logo.png
GBT Announces Participation at the Goldman Sachs 42nd Annual Global Healthcare Conference
June 01, 2021 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd...
GBT new logo.png
GBT présentera prochainement ses données à l’occasion du Congrès virtuel 2021 de l'Association européenne d'hématologie (EHA)
May 12, 2021 10:05 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Californie, 12 mai 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ : GBT) a annoncé aujourd'hui que six abstracts relatifs à son programme de...
GBT new logo.png
GBT kündigt Präsentation von Daten auf dem virtuellen Kongress der European Hematology Association (EHA) 2021 an
May 12, 2021 10:05 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Kalifornien, May 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) kündigte heute an, dass auf dem Virtuellen Kongress der European Hematology...